Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
| Status: | Terminated |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 6/30/2018 |
| Start Date: | July 2012 |
| End Date: | March 2014 |
A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride
Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with
metformin.
Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with
metformin.
Inclusion Criteria:
- BMI >/= 25 to
- Type 2 Diabetes Mellitus and on a stable dose of metformin
- Hypertriglyceridemia
Exclusion Criteria:
- Significant abnormalities in medical history, clinical examination or clinical testing
- Use of oral anti-diabetic medication other than metformin within 3 months prior to
dosing
- History of outpatient insulin use for more than 2 weeks in the last year
We found this trial at
1
site
Click here to add this to my saved trials
